Show document

A+ | A- | | SLO | ENG

Title: Sistemsko zdravljenje napredovalega medularnega karcinoma ščitnice Authors: ID Grašič-Kuhar, Cvetka (Author) Files: PDF - Presentation file, download (430,68 KB)   Language: Slovenian Typology: 1.02 - Review Article Organization: OI - Institute of Oncology Abstract: Medularni karcinom ščitnice nastane iz nevroendokrinih celic ščitnice, ki izločajo kalcitonin. Kalcitonin je specifičen marker medularnega raka ščitnice. Pri lokalno napredovalem ali metastaskem medularnem raku ščitnice ob simptomtskem progresu prihaja v poštev zdravljenje s tirozin kinaznimi inhibitorji. Registrirani substanci sta vandetanib in cabozantinib, učinkoviti pa sta tudi sorafenib in sunitinib. Izbira zdravljenja je individualizirana glede na breme bolezni in spremljajoče bolezni. Zelo pomembno je tudi podporno (na simptome usmerjeno) zdravljenje. Keywords: medularni karcinom ščitnice, rak ščitnice, sistemsko zdravljenje, napredovali rak Publication status: Published Publication version: Version of Record Year of publishing: 2016 Number of pages: str. 4-6 Numbering: Letn. 20, št. 1 COBISS.SI-ID: 2415739  UDC: 616.4 ISSN on article: 1408-1741 Publication date in DiRROS: 03.01.2018 Views: 598 Downloads: 14 Metadata:    Cite this work Plain text BibTeX EndNote XML EndNote/Refer RIS ABNT ACM Ref AMA APA Chicago 17th Author-Date Harvard IEEE ISO 690 MLA Vancouver : Copy citation

Share: Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Secondary language

Language:	English
Title:	Systemic Treatment of Advanced Medullary Thyroid Carcinoma
Abstract:	Medullary thyroid carcinoma originates from neuroendocrine cells of the thyroid which secrete calcitonin. Calcitonin is a specific marker for medullary thyroid cancer. Therapy with tyrosine kinase inhibitors can be applied to treat locally advanced or metastatic medullary thyroid cancer with progressing symptoms. Registered substances used are vandetanib and cabozantinib, and sorafenib and sunitinib are also effective. Treatment is determined individually based on the burden of the cancer and secondary diseases. Supportive treatment (targeted at the symptoms) is also very important.
Keywords:	systemic treatment, medullary thyroid carcinoma, thyroid cancer

Collection

This document is a part of these collections:

1. Onkologija : strokovni časopis za zdravnike

Back